Skip to main content

As France moves closer to legalizing medical cannabis, Newsweed and consulting firm Augur Associates have released a comprehensive report titled “State of the Medical Cannabis Industry in France.” This in‑depth study, the result of several months of research, offers a detailed overview of France’s emerging medical cannabis landscape.

A Landscape in Flux

France has made initial progress with a tightly regulated pilot program overseen by ANSM (France’s National Agency for Medicines and Health Products Safety). This trial, which began in March 2021, involves roughly 2,100 patients out of an expected 3,000 and relies exclusively on imported cannabis products—no domestic production has yet been launched .

The central questions now are:

  • What will France’s permanent legal framework look like?

  • How will pharmaceutical companies fit into the system?

  • What will be the healthcare system’s specific requirements?

  • How will private-sector players be included?

The report answers these questions using strategic analysis, regulatory monitoring, and insights from European experiences.

ANSM France Cannabis Trials 2025

Intended Audience

The report is aimed at a broad spectrum of stakeholders, including:

  • Medical cannabis and pharmaceutical companies

  • Investors and specialized funds

  • Healthcare professionals

  • Institutional decision‑makers and policymakers

  • Journalists and market analysts

  • Anyone curious about the subject

Its objective is to offer a pragmatic, operationally focused view of France’s upcoming market, framed within the context of varied European regulatory models.

A Pivotal Moment

Released at the end of June 2025, the report—available in both French and English—covers:

  • The existing regulatory framework and upcoming changes

  • Key market players and the role of the French healthcare system

  • A uniquely pharmaceutical approach within Europe

  • Business barriers and opportunities

  • Realistic market data

  • Strategic expert analysis

If France approves a permanent, well-structured model, the implications could significantly impact patients, healthcare providers, and the entire industry.

Free Access and Availability

The full report is publicly accessible and free to download in both French and English from the Augur Associates’ website.

"State of the Medical Cannabis Industry in France" a report by Newsweed and Augur Associates
ZuriCan sign in Zurich, Switzerland on cannabis policy
Zurich Extends Legal Cannabis Pilot Programme to 2028European Cannabis Industry

Zurich Extends Legal Cannabis Pilot Programme to 2028

Roberto PerezRoberto PerezOctober 27, 2025
343 Cannabis Social Clubs now in Germany
343 Licensed Cannabis Clubs now in GermanyEuropean Cannabis Industry

343 Licensed Cannabis Clubs now in Germany

Roberto PerezRoberto PerezOctober 24, 2025
Medical Cannabis in the Spotlight, Whilst Other Substances Go UnchallengedEuropean Cannabis Industry

Medical Cannabis in the Spotlight, Whilst Other Substances Go Unchallenged

Roberto PerezRoberto PerezAugust 27, 2025